Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Steven M. Opal; Pierre-Francois Laterre; Bruno Francois; Steven P. LaRosa; Derek C. Angus; Jean-Paul Mira; Xavier Wittebole; Thierry Dugernier; Dominique Perrotin; Mark Tidswell; Luis Jauregui; Kenneth Krell; Jan Pachl; Takeshi Takahashi; Claus Peckelsen; Edward Cordasco; Chia-Sheng Chang; Sandra Oeyen; Naoki Aikawa; Tatsuya Maruyama; Roland Schein; Andre C. Kalil; Marc Van Nuffelen; Melvyn Lynn; Daniel P. Rossignol; Jagadish Gogate; Mary B. Roberts; Mary B. Roberts; Janice L. Wheeler; Jean-Louis Vincent

doi:10.1001/JAMA.2013.2194

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Steven M. Opal
, Pierre-Francois Laterre
, Bruno Francois
, Steven P. LaRosa
, Derek C. Angus
, Jean-Paul Mira
, Xavier Wittebole
, Thierry Dugernier
, Dominique Perrotin
, Mark Tidswell
, Luis Jauregui
, Kenneth Krell
, Jan Pachl
, Takeshi Takahashi
, Claus Peckelsen
, Edward Cordasco
, Chia-Sheng Chang
, Sandra Oeyen
, Naoki Aikawa
, Tatsuya Maruyama

Roland Schein, Andre C. Kalil, Marc Van Nuffelen, Melvyn Lynn, Daniel P. Rossignol, Jagadish Gogate, Mary B. Roberts, Mary B. Roberts, Janice L. Wheeler, Jean-Louis Vincent

Brown University
Université catholique de Louvain
Hôpital Dupuytren
Scott & White Hospital
University of Pittsburgh
University of Paris
Clinique Saint-Pierre of Ottignies
François Rabelais University
Tufts University
Mercy Health Partners
Eastern Idaho Regional Med Center
Charles University in Prague
München Klinik Bogenhausen
Remington-Davis, Inc.
China Medical University (Taiwan)
Ghent University
Keio University
University of Miami
University of Nebraska Medical Center
Eisai
Memorial Hospital of Rhode Island
Universite Libre de Bruxelles

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	JAMA
Volume	309
Issue number	11
DOIs	https://doi.org/10.1001/JAMA.2013.2194
State	Published - Mar 20 2013
Externally published	Yes

Disciplines

Medicine and Health Sciences
Surgery
Internal Medicine

Access to Document

10.1001/JAMA.2013.2194License: Unspecified

Cite this

Opal, S. M., Laterre, P.-F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J.-P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., Jauregui, L., Krell, K., Pachl, J., Takahashi, T., Peckelsen, C., Cordasco, E., Chang, C.-S., Oeyen, S., Aikawa, N., ... Vincent, J.-L. (2013). Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA, 309(11). https://doi.org/10.1001/JAMA.2013.2194

Opal, SM, Laterre, P-F, Francois, B, LaRosa, SP, Angus, DC, Mira, J-P, Wittebole, X, Dugernier, T, Perrotin, D, Tidswell, M, Jauregui, L, Krell, K, Pachl, J, Takahashi, T, Peckelsen, C, Cordasco, E, Chang, C-S, Oeyen, S, Aikawa, N, Maruyama, T, Schein, R, Kalil, AC, Van Nuffelen, M, Lynn, M, Rossignol, DP, Gogate, J, Roberts, MB, Roberts, MB, Wheeler, JL & Vincent, J-L 2013, 'Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.', JAMA, vol. 309, no. 11. https://doi.org/10.1001/JAMA.2013.2194

@article{402bd40170164cdab72346b8069f5c9e,

title = "Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.",

author = "Opal, \{Steven M.\} and Pierre-Francois Laterre and Bruno Francois and LaRosa, \{Steven P.\} and Angus, \{Derek C.\} and Jean-Paul Mira and Xavier Wittebole and Thierry Dugernier and Dominique Perrotin and Mark Tidswell and Luis Jauregui and Kenneth Krell and Jan Pachl and Takeshi Takahashi and Claus Peckelsen and Edward Cordasco and Chia-Sheng Chang and Sandra Oeyen and Naoki Aikawa and Tatsuya Maruyama and Roland Schein and Kalil, \{Andre C.\} and \{Van Nuffelen\}, Marc and Melvyn Lynn and Rossignol, \{Daniel P.\} and Jagadish Gogate and Roberts, \{Mary B.\} and Roberts, \{Mary B.\} and Wheeler, \{Janice L.\} and Jean-Louis Vincent",

year = "2013",

month = mar,

day = "20",

doi = "10.1001/JAMA.2013.2194",

language = "American English",

volume = "309",

journal = "JAMA",

issn = "1538-3598",

publisher = "American Medical Association",

number = "11",

}

TY - JOUR

T1 - Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

AU - Opal, Steven M.

AU - Laterre, Pierre-Francois

AU - Francois, Bruno

AU - LaRosa, Steven P.

AU - Angus, Derek C.

AU - Mira, Jean-Paul

AU - Wittebole, Xavier

AU - Dugernier, Thierry

AU - Perrotin, Dominique

AU - Tidswell, Mark

AU - Jauregui, Luis

AU - Krell, Kenneth

AU - Pachl, Jan

AU - Takahashi, Takeshi

AU - Peckelsen, Claus

AU - Cordasco, Edward

AU - Chang, Chia-Sheng

AU - Oeyen, Sandra

AU - Aikawa, Naoki

AU - Maruyama, Tatsuya

AU - Schein, Roland

AU - Kalil, Andre C.

AU - Van Nuffelen, Marc

AU - Lynn, Melvyn

AU - Rossignol, Daniel P.

AU - Gogate, Jagadish

AU - Roberts, Mary B.

AU - Wheeler, Janice L.

AU - Vincent, Jean-Louis

PY - 2013/3/20

Y1 - 2013/3/20

UR - https://jamanetwork.com/journals/jama/articlepdf/1669798/jce130005_1154_1162.pdf

U2 - 10.1001/JAMA.2013.2194

DO - 10.1001/JAMA.2013.2194

M3 - Article

SN - 1538-3598

VL - 309

JO - JAMA

JF - JAMA

IS - 11

ER -

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

Disciplines

Access to Document

Other files and links

Cite this